Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration

10 January 2023 | Tuesday | News

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a research collaboration with Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) to discover antibodies against multiple targets of interest to develop curative therapies for patients suffering from diseases that lack treatment options.
Image Source : Public Domain

Image Source : Public Domain

“This second collaboration with Astellas demonstrates the power of our antibody discovery capabilities. The depth and breadth of our Library of Libraries enables highly potent antibodies, often missed using other technologies, to be identified across multiple potential therapeutic areas,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We are looking forward to continuing our working relationship with Astellas and building on the progress made to date in our first collaboration.”

Under the terms of the agreement, Twist will conduct antibody discovery activities against multiple targets identified by Astellas. In addition to an upfront payment and project specific research fees, Twist will be eligible to receive up to $11 million USD per product through payments associated with specific clinical and commercial milestones. Twist will also be eligible to receive royalty payments on product sales. Astellas will be responsible for the development, manufacturing and commercialization of any such products.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in